Prime Medicine Statistics
Total Valuation
Prime Medicine has a market cap or net worth of $507.54 million. The enterprise value is $486.55 million.
Important Dates
The last earnings date was Thursday, May 7, 2026, before market open.
| Earnings Date | May 7, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Prime Medicine has 180.62 million shares outstanding. The number of shares has increased by 28.04% in one year.
| Current Share Class | 180.62M |
| Shares Outstanding | 180.62M |
| Shares Change (YoY) | +28.04% |
| Shares Change (QoQ) | -0.11% |
| Owned by Insiders (%) | 14.30% |
| Owned by Institutions (%) | 48.49% |
| Float | 108.73M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 125.81 |
| Forward PS | n/a |
| PB Ratio | 6.62 |
| P/TBV Ratio | 6.62 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 120.61 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.80, with a Debt / Equity ratio of 1.49.
| Current Ratio | 3.80 |
| Quick Ratio | 3.73 |
| Debt / Equity | 1.49 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -216.07% and return on invested capital (ROIC) is -61.60%.
| Return on Equity (ROE) | -216.07% |
| Return on Assets (ROA) | -41.46% |
| Return on Invested Capital (ROIC) | -61.60% |
| Return on Capital Employed (ROCE) | -79.95% |
| Weighted Average Cost of Capital (WACC) | 14.04% |
| Revenue Per Employee | $27,630 |
| Profits Per Employee | -$1.36M |
| Employee Count | 146 |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +76.73% in the last 52 weeks. The beta is 2.36, so Prime Medicine's price volatility has been higher than the market average.
| Beta (5Y) | 2.36 |
| 52-Week Price Change | +76.73% |
| 50-Day Moving Average | 3.54 |
| 200-Day Moving Average | 4.01 |
| Relative Strength Index (RSI) | 29.31 |
| Average Volume (20 Days) | 2,304,928 |
Short Selling Information
The latest short interest is 30.35 million, so 16.80% of the outstanding shares have been sold short.
| Short Interest | 30.35M |
| Short Previous Month | 30.24M |
| Short % of Shares Out | 16.80% |
| Short % of Float | 27.91% |
| Short Ratio (days to cover) | 16.36 |
Income Statement
In the last 12 months, Prime Medicine had revenue of $4.03 million and -$198.37 million in losses. Loss per share was -$1.24.
| Revenue | 4.03M |
| Gross Profit | -150.15M |
| Operating Income | -206.61M |
| Pretax Income | -198.37M |
| Net Income | -198.37M |
| EBITDA | -199.14M |
| EBIT | -206.61M |
| Loss Per Share | -$1.24 |
Full Income StatementBalance Sheet
The company has $135.50 million in cash and $114.51 million in debt, with a net cash position of $20.99 million or $0.12 per share.
| Cash & Cash Equivalents | 135.50M |
| Total Debt | 114.51M |
| Net Cash | 20.99M |
| Net Cash Per Share | $0.12 |
| Equity (Book Value) | 76.70M |
| Book Value Per Share | 0.42 |
| Working Capital | 101.60M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$156.42 million and capital expenditures -$2.32 million, giving a free cash flow of -$158.74 million.
| Operating Cash Flow | -156.42M |
| Capital Expenditures | -2.32M |
| Depreciation & Amortization | 7.48M |
| Net Borrowing | n/a |
| Free Cash Flow | -158.74M |
| FCF Per Share | -$0.88 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | -5,121.77% |
| Pretax Margin | -4,917.55% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Prime Medicine does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -28.04% |
| Shareholder Yield | -28.04% |
| Earnings Yield | -39.09% |
| FCF Yield | -31.28% |
Analyst Forecast
The average price target for Prime Medicine is $6.92, which is 146.26% higher than the current price. The consensus rating is "Buy".
| Price Target | $6.92 |
| Price Target Difference | 146.26% |
| Analyst Consensus | Buy |
| Analyst Count | 13 |
| Revenue Growth Forecast (5Y) | 104.21% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Prime Medicine has an Altman Z-Score of -4.77 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -4.77 |
| Piotroski F-Score | 3 |
